Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for diabetes and pulmonary arterial hypertension patients in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. The company has a license and collaboration agreement with United Therapeutics Corporation for the development and commercialization of a dry powder formulation of treprostinil used for the treatment of pulmonary arterial hypertension. MannKind Corporation was founded in 1991 and is headquartered in Westlake Village, California.
Website: mannkindcorp.com



Growth: Good revenue growth rate 61.1%, there is acceleration compared to average historical growth rates 61.0%. The revenue growth dynamics is unstable

Profitability: LTM EBITDA margin is positive, +7.0%. On average the margin is improving steadily. Gross margin is high, +69.1%. In the last quarter the company beat the estimated EPS. The company was ahead of estimated EPS in 60% of quarters (showing a gain of $0.00 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield 11.5% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 70.6% higher than minimum and 20.6% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 5.0x by EV / Sales multiple , the company can be 10.5% overvalued

Key Financials (Download financials)

Ticker: MNKD
Share price, USD:  (+1.6%)4.47
year average price 4.13  


year start price 4.40 2023-05-10

max close price 5.45 2023-08-08

min close price 3.25 2024-02-05

current price 4.47 2024-05-08
Common stocks: 252 564 994

Dividend Yield:  0.0%
FCF Yield LTM: 11.5%
EV / LTM EBITDA: 79.1x
EV / EBITDA annualized: 27.7x
Last revenue growth (y/y):  61.1%
Last growth of EBITDA (y/y):  ---
Historical revenue growth:  61.0%
Historical growth of EBITDA:  50.0%
EV / Sales: 5.6x
Margin (EBITDA LTM / Revenue): 7.0%
Fundamental value created in LTM:
Market Cap ($m): 1 129
Net Debt ($m): -22
EV (Enterprise Value): 1 107
Price to Book: -4.5x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2024-03-04GlobeNewsWire

MannKind Corporation Announces Participation at Upcoming Conferences

2024-02-27Seeking Alpha

MannKind Corporation (MNKD) Q4 2023 Earnings Call Transcript

2024-02-27Zacks Investment Research

Here's What Key Metrics Tell Us About MannKind (MNKD) Q4 Earnings

2024-02-27Zacks Investment Research

MannKind (MNKD) Q4 Earnings and Revenues Surpass Estimates

2024-02-14Seeking Alpha

MannKind's Tyvaso DPI Royalty Deal Signals Undervaluation

2024-01-02Market Watch

MannKind in royalty agreement with Sagard Healthcare for Tyvaso DPI

2023-11-07Zacks Investment Research

MannKind (MNKD) Reports Q3 Earnings: What Key Metrics Have to Say

2023-10-31GlobeNewsWire

MannKind Corporation to Hold 2023 Third Quarter Financial Results Conference Call on November 7, 2023

2023-10-18Seeking Alpha

Tyvaso DPI Is Breathing New Life Into MannKind's Balance Sheet (Rating Upgrade)

2023-08-08The Motley Fool

Why MannKind Stock Soared 19% Higher on Tuesday
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol MNKD MNKD MNKD MNKD MNKD MNKD
reportedCurrency USD USD USD USD USD USD
cik 899 460 899 460 899 460 899 460 899 460 899 460
fillingDate 2024-02-27 2023-11-07 2023-08-07 2023-05-09 2023-02-23 2022-11-08
acceptedDate 2024-02-27 17:23:29 2023-11-07 16:11:17 2023-08-07 16:12:08 2023-05-09 16:11:51 2023-02-23 16:11:49 2022-11-08 08:08:32
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
revenue 58M 51M 49M 41M 36M 33M
costOfRevenue 18M 14M 14M 16M 16M 17M
grossProfit 40M 37M 34M 24M 20M 15M
grossProfitRatio 0.691 0.722 0.707 0.601 0.553 0.468
researchAndDevelopmentExpenses 9M 10M 6M 6M 7M 4M
generalAndAdministrativeExpenses 10M 11M 12M 11M 10M 23M
sellingAndMarketingExpenses 11M 13M 14M 13M 12M 0
sellingGeneralAndAdministrativeExpenses 21M 24M 26M 24M 22M 23M
otherExpenses -164 000 318 000 -143 000 111 000 105 000 0
operatingExpenses 30M 34M 32M 29M 29M 27M
costAndExpenses 48M 48M 47M 46M 45M 44M
interestIncome 2M 2M 2M 1M 957 000 663 000
interestExpense 5M 5M 9M 5M 5M 5M
depreciationAndAmortization 2M 1M 1M 1M 1M 3M
ebitda 12M 6M 3M -4M -8M -9M
ebitdaratio 0.209 0.125 0.069 -0.089 -0.229 -0.270
operatingIncome 11M 5M 2M -5M -9M -11M
operatingIncomeRatio 0.182 0.099 0.035 -0.124 -0.258 -0.348
totalOtherIncomeExpensesNet -8M 2M 538 000 -5M -9M -3M
incomeBeforeTax 3M 2M -5M -10M -18M -14M
incomeBeforeTaxRatio 0.051 0.034 -0.108 -0.241 -0.498 -0.440
incomeTaxExpense 2M 6M 8M 6M 5M 5M
netIncome 1M 2M -5M -16M -23M -20M
netIncomeRatio 0.024 0.034 -0.108 -0.394 -0.644 -0.600
eps 0.005 0.006 -0.020 -0.061 -0.088 -0.076
epsdiluted 0.004 0.006 -0.020 -0.061 -0.088 -0.076
weightedAverageShsOut 270M 269M 266M 264M 263M 259M
weightedAverageShsOutDil 324M 269M 266M 264M 263M 259M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Balance Sheet Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol MNKD MNKD MNKD MNKD MNKD MNKD
reportedCurrency USD USD USD USD USD USD
cik 899 460 899 460 899 460 899 460 899 460 899 460
fillingDate 2024-02-27 2023-11-07 2023-08-07 2023-05-09 2023-02-23 2022-11-08
acceptedDate 2024-02-27 17:23:29 2023-11-07 16:11:17 2023-08-07 16:12:08 2023-05-09 16:11:51 2023-02-23 16:11:49 2022-11-08 08:08:32
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 238M 83M 86M 86M 70M 54M
shortTermInvestments 57M 58M 58M 80M 101M 111M
cashAndShortTermInvestments 295M 141M 144M 166M 171M 165M
netReceivables 15M 22M 28M 20M 17M 23M
inventory 29M 27M 25M 22M 22M 18M
otherCurrentAssets 34M 36M 33M 15M 25M 12M
totalCurrentAssets 373M 226M 230M 223M 235M 218M
propertyPlantEquipmentNet 89M 80M 70M 55M 45M 41M
goodwill 2M 2M 2M 2M 2M 3M
intangibleAssets 1M 1M 1M 1M 1M 1M
goodwillAndIntangibleAssets 3M 3M 3M 3M 4M 4M
longTermInvestments 7M 3M 2M 492 000 2M 13M
taxAssets 1M 0 0 0 0 0
otherNonCurrentAssets 2M 8M 8M 16M 10M 17M
totalNonCurrentAssets 102M 95M 83M 75M 60M 75M
otherAssets 0 0 0 0 0 0
totalAssets 475M 320M 313M 298M 295M 294M
accountPayables 10M 17M 17M 14M 11M 10M
shortTermDebt 32M 20M 26M 21M 10M 10M
taxPayables 2M 0 0 0 0 0
deferredRevenue 9M 4M 3M 2M 2M 2M
otherCurrentLiabilities 53M 56M 50M 44M 45M 38M
totalCurrentLiabilities 104M 96M 97M 82M 67M 60M
longTermDebt 252M 258M 357M 362M 373M 279M
deferredRevenueNonCurrent 70M 69M 60M 46M 38M 32M
deferredTaxLiabilitiesNonCurrent 98M 57 000 55 000 0 0 0
otherNonCurrentLiabilities 197M 149M 60M 64M 67M 451M
totalNonCurrentLiabilities 617M 476M 477M 472M 479M 472M
otherLiabilities 0 0 0 0 0 0
capitalLeaseObligations 98M 4M 5M 5M 5M 6M
totalLiabilities 721M 572M 574M 554M 546M 532M
preferredStock 0 0 0 0 0 0
commonStock 3M 3M 3M 3M 3M 3M
retainedEarnings -3 229M -3 231M -3 233M -3 227M -3 217M -3 200M
accumulatedOtherComprehensiveIncomeLoss 0 443 000 443 000 0 0 -1M
othertotalStockholdersEquity 2 981M 2 976M 2 969M 2 969M 2 964M 2 960M
totalStockholdersEquity -246M -252M -260M -255M -251M -238M
totalEquity -246M -252M -260M -255M -251M -238M
totalLiabilitiesAndStockholdersEquity 475M 320M 313M 298M 295M 294M
minorityInterest 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 475M 320M 313M 298M 295M 294M
totalInvestments 64M 61M 60M 81M 103M 123M
totalDebt 382M 278M 383M 383M 383M 288M
netDebt 144M 195M 297M 297M 313M 234M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Cash Flow Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol MNKD MNKD MNKD MNKD MNKD MNKD
reportedCurrency USD USD USD USD USD USD
cik 899 460 899 460 899 460 899 460 899 460 899 460
fillingDate 2024-02-27 2023-11-07 2023-08-07 2023-05-09 2023-02-23 2022-11-08
acceptedDate 2024-02-27 17:23:29 2023-11-07 16:11:17 2023-08-07 16:12:08 2023-05-09 16:11:51 2023-02-23 16:11:49 2022-11-08 08:08:32
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
netIncome 1M 2M -5M -10M -18M -14M
depreciationAndAmortization 2M 1M 1M 1M 2M 2M
deferredIncomeTax -9M -2M 262 000 0 0 0
stockBasedCompensation 4M 5M 6M 4M 3M 4M
changeInWorkingCapital 10M 14M -2M -468 000 3M -17M
accountsReceivables 7M 6M -8M -3M 7M -8M
inventory -2M -2M -4M -3M -4M 1M
accountsPayables -7M -373 000 3M 3M 1M 2M
otherWorkingCapital 12M 10M 7M 2M -254 000 -12M
otherNonCashItems 14M -11M 3M 6M 8M -2M
netCashProvidedByOperatingActivities 22M 9M 3M 1M -2M -28M
investmentsInPropertyPlantAndEquipment -6M -11M -17M -8M -5M -271 000
acquisitionsNet 2M 0 -21M 0 -242 000 0
purchasesOfInvestments -29M -24M -26M 0 -4M -2M
salesMaturitiesOfInvestments 27M 24M 47M 22M 25M 29M
otherInvestingActivites -2M 382 000 21M 0 0 0
netCashUsedForInvestingActivites -8M -12M 4M 14M 15M 27M
debtRepayment -141M -2M -43 000 -72 000 -18 000 -1M
commonStockIssued -1M 5M 2M 1M -684 000 20M
commonStockRepurchased 38 000 -2M -8M 0 0 0
dividendsPaid 0 0 -8M 0 0 0
otherFinancingActivites 284M -4M 9M 28 000 4M 1M
netCashUsedProvidedByFinancingActivities 142M -283 000 -6M 1M 3M 20M
effectOfForexChangesOnCash 0 0 0 0 0 0
netChangeInCash 155M -3M 315 000 16M 15M 19M
cashAtEndOfPeriod 238M 83M 86M 86M 70M 54M
cashAtBeginningOfPeriod 83M 86M 86M 70M 54M 36M
operatingCashFlow 22M 9M 3M 1M -2M -28M
capitalExpenditure -6M -11M -17M -8M -5M -271 000
freeCashFlow 16M -3M -14M -7M -7M -28M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Earning call transcript

2023 q4
2024-02-27 ET (fiscal 2023 q4)
2023 q3
2023-11-07 ET (fiscal 2023 q3)
2023 q2
2023-08-08 ET (fiscal 2023 q2)
2023 q1
2023-05-09 ET (fiscal 2023 q1)
2022 q4
2023-02-24 ET (fiscal 2022 q4)
2022 q3
2022-11-08 ET (fiscal 2022 q3)
2022 q2
2022-08-09 ET (fiscal 2022 q2)
2022 q1
2022-05-05 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2024-05-06 10:05 ET
MannKind Receives U.S. FDA Fast Track Designation for Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease
2024-05-01 20:00 ET
MannKind Corporation to Hold 2024 First Quarter Financial Results Conference Call on May 8, 2024
2024-04-30 10:05 ET
MannKind to Proceed With Phase 1 Nintedanib Dpi (Mnkd-201) Study for Pulmonary Fibrotic Diseases
2024-04-29 10:05 ET
MannKind Announces IND Clearance From U.S. FDA to Start Phase 3 Study of Clofazimine Inhalation Suspension for Nontuberculous Mycobacterial (NTM) Lung Disease
2024-04-03 10:00 ET
MannKind Repays Certain Debt Obligations
2024-03-26 20:05 ET
MannKind Announces CFO Transition
2024-03-11 10:05 ET
INHALE-3 Study’s Initial Meal Challenge Results Comparing Afrezza® Head-To-Head With Multiple Daily Injections (MDI) and Insulin Pumps
2024-03-05 11:05 ET
MannKind Announces New Clinical Data From Inhale-3 Study to be Presented by Dr. Irl B. Hirsch at ATTD on March 8
2024-03-04 18:01 ET
MannKind Corporation Announces Participation at Upcoming Conferences
2024-02-27 21:00 ET
MannKind Corporation Reports 2023 Fourth Quarter and Full Year Financial Results: Provides Clinical Development Update
2024-02-20 11:00 ET
MannKind Corporation to Hold 2023 Fourth Quarter and Full Year Financial Results Conference Call on February 27, 2024
2024-02-15 11:05 ET
MannKind Announces Enrollment Goal Completion of INHALE-1 Pediatric Diabetes Trial Utilizing Afrezza®
2024-01-02 11:05 ET
MannKind and Sagard Healthcare Enter Into Royalty Purchase Agreement for Up to $200 Million
2023-12-28 11:00 ET
MannKind Corporation to Present at 42nd Annual J.P. Morgan Healthcare Conference
2023-11-07 21:00 ET
MannKind Corporation Reports 2023 Third Quarter Financial Results
2023-11-06 11:15 ET
MannKind Announces Completion of Enrollment in U.S. Phase 4 Inhale-3 Clinical Trial in Patients Living With Type 1 Diabetes
2023-10-31 20:00 ET
MannKind Corporation to Hold 2023 Third Quarter Financial Results Conference Call on November 7, 2023
2023-10-30 10:15 ET
MannKind Expands Patent Portfolio With New Clofazimine Formulation Patent
2023-09-05 10:00 ET
MannKind Corporation Announces Participation at Upcoming Conferences
2023-08-07 20:00 ET
MannKind Corporation Reports 2023 Second Quarter Financial Results
2023-08-01 10:00 ET
MannKind Corporation Announces Participation in the 2023 Wedbush PacGrow Healthcare Conference
2023-07-31 20:00 ET
MannKind Corporation to Hold 2023 Second Quarter Financial Results Conference Call on August 7, 2023
2023-06-22 10:05 ET
MannKind Launches Inhale-3 Study to Address the Most Important Unmet Need Today in Adults Living With Type 1 Diabetes (T1D)
2023-06-11 12:05 ET
Governor Ned Lamont to Tour MannKind June 12 as It Reaches a Manufacturing Milestone
2023-05-24 12:30 ET
Dr. Burkhard Blank Joins MannKind as Executive Vice President of Research & Development and Chief Medical Officer
2023-05-10 10:00 ET
MannKind Corporation to Participate in the 2023 RBC Capital Markets Global Healthcare Conference
2023-05-09 20:00 ET
Mannkind Corporation Reports 2023 First Quarter Financial Results
2023-05-02 21:00 ET
MannKind Corporation to Hold 2023 First Quarter Financial Results Conference Call on May 9, 2023
2023-03-27 20:05 ET
Lauren Sabella Joins Mannkind as Executive Vice President, Chief Operating Officer
2023-03-07 22:00 ET
MannKind Corporation to Participate in Oppenheimer 33rd Annual Healthcare Conference
2023-02-23 21:00 ET
MannKind Corporation Reports 2022 Fourth Quarter and Full Year Financial Results
2023-02-22 11:05 ET
MannKind to Give Oral Presentation on Meal Challenge Results From the Afrezza® With Basal Combination (ABC Study) at 16th Annual ATTD Conference
2023-02-16 22:00 ET
MannKind Corporation to Hold 2022 Fourth Quarter and Full Year Financial Results Conference Call on February 23, 2023
2023-02-10 22:00 ET
Mannkind Corporation to Participate in the SVB Securities Global Biopharma Conference
2023-01-24 11:00 ET
MannKind Corporation to Participate in the Lytham Partners Investor Select Conference
2023-01-23 11:05 ET
MannKind’s Inhaled Clofazimine Will Advance to an Adaptive Phase 2/3 Study For Potential Treatment of Rare Lung Disease
2023-01-05 11:00 ET
MannKind Corporation to Present at 2023 Annual J.P. Morgan Healthcare Conference
2022-11-10 11:05 ET
MannKind to Present Two Posters at 22nd Annual Diabetes Technology Meeting
2022-11-08 13:00 ET
MannKind Corporation Reports 2022 Third Quarter Financial Results
2022-11-01 10:00 ET
MannKind Corporation to Hold 2022 Third Quarter Financial Results Conference Call on November 8, 2022
2022-09-21 21:00 ET
MannKind Corporation to Participate in the Lytham Partners Fall 2022 Investor Conference
2022-09-06 10:15 ET
Mannkind Successfully Completes Phase 1 Study of Inhaled Clofazimine
2022-09-01 10:00 ET
MannKind Corporation to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
2022-08-09 20:00 ET
MannKind Corporation Reports 2022 Second Quarter Financial Results
2022-08-02 10:00 ET
MannKind Corporation to Hold 2022 Second Quarter Financial Results Conference Call on August 9, 2022
2022-08-01 10:00 ET
MannKind Corporation to Participate in the BTIG Biotechnology Conference
2022-06-03 14:00 ET
Mannkind to Host Product Theater and Booth at the American Diabetes Association’s 82nd Scientific Sessions in New Orleans, June 3-7
2022-05-24 10:00 ET
MannKind’s Technosphere® Inhalation Platform Utilized in FDA-Approved Tyvaso DPI™
2022-05-19 10:00 ET
MannKind Corporation to Ring the Nasdaq Stock Market Opening Bell
2022-05-17 10:06 ET
MannKind Corporation Announces Agreement to Acquire V-Go® Insulin Delivery Device From Zealand Pharma
2022-05-09 10:00 ET
MannKind Corporation Participating at Upcoming Conferences
2022-05-05 20:00 ET
MannKind Corporation Reports 2022 First Quarter Financial Results
2022-04-28 10:00 ET
MannKind Corporation to Hold 2022 First Quarter Financial Results Conference Call on May 5, 2022
2022-04-27 10:05 ET
MannKind Presents Poster at 15th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2022) to Be Held April 27-30
2022-03-28 10:05 ET
MannKind Corporation to Participate in the Lytham Partners Spring 2022 Investor Conference
2022-03-22 10:05 ET
MannKind Corporation to Participate in the Cantor Virtual Rare Orphan Disease Summit
2022-03-08 11:05 ET
MannKind Corporation to Participate in Oppenheimer 32nd Annual Healthcare Conference
2022-02-24 21:00 ET
MannKind Corporation Reports 2021 Fourth Quarter and Full Year Financial Results
2022-02-24 11:05 ET
Update on Tyvaso DPI™ New Drug Application
2022-02-21 14:05 ET
MannKind Corporation to Hold 2021 Fourth Quarter and Full Year Financial Results Conference Call on February 24, 2022
2022-02-10 11:05 ET
MannKind Corporation to Participate in SVB Leerink 2022 Global Healthcare Conference
2022-01-05 11:10 ET
MannKind Corporation to Participate in H.C. Wainwright Bioconnect Conference
2022-01-05 11:05 ET
MannKind Extends Collaboration With Thirona Bio on Fibrotic Lung Diseases
2021-12-06 11:05 ET
MannKind Corporation to Participate in the Lytham Partners Winter 2021 Investor Conference
2021-11-09 21:05 ET
MannKind Corporation Reports 2021 Third Quarter Financial Results
2021-11-09 11:05 ET
Mannkind Corporation Closes Sale-Leaseback Transaction Generating $102.25 Million in Non-Dilutive Gross Proceeds
2021-11-05 11:05 ET
MannKind Presents Data at 21st Annual Diabetes Technology Meeting
2021-11-02 10:05 ET
MannKind Corporation to Hold 2021 Third Quarter Financial Results Conference Call on November 9, 2021
2021-10-18 10:00 ET
Progress Update on Tyvaso DPI™ New Drug Application
2021-10-04 11:05 ET
MannKind Announces First Patient Enrolled in INHALE-1 Study of Afrezza® in Pediatric Population
2021-10-04 11:05 ET
MannKind Announces First Patient Enrolled In Inhale-1 Study Of Afrezza® In Pediatric Population
2021-09-29 20:24 ET
Mannkind Corporation Announces Sale-Leaseback Transaction Generating $102.25 Million in Non-Dilutive Gross Proceeds
2021-09-28 10:05 ET
MannKind Corporation to Participate at Lytham Partners Fall 2021 Investor Conference
2021-09-15 10:05 ET
Mannkind Corporation Participating at Upcoming Conferences
2021-09-07 10:05 ET
MannKind Corporation to Participate in H.C. Wainwright 23rd Annual Global Investment Conference
2021-09-07 10:00 ET
United Therapeutics Presents Tyvaso DPI™ BREEZE Clinical Data At The European Respiratory Society International Congress 2021
2021-08-24 10:00 ET
United Therapeutics to Present Tyvaso DPI™ BREEZE Clinical Data at the European Respiratory Society International Congress 2021
2021-08-11 20:00 ET
MannKind Corporation Reports 2021 Second Quarter Financial Results
2021-08-04 10:48 ET
MannKind Partners With NRx Pharmaceuticals To Explore A Dry Powder Formulation Of ZYESAMI™ (aviptadil) Based On The Technosphere® Platform
2021-08-04 10:48 ET
NRx Pharmaceuticals Partners with MannKind Corporation to Develop ZYESAMI™ (aviptadil) Inhaler for Respiratory Conditions
2021-08-04 10:15 ET
MannKind Corporation to Hold 2021 Second Quarter Financial Results Conference Call on August 11, 2021
2021-08-03 13:00 ET
MannKind Corporation to Participate in the BTIG Virtual Biotechnology Conference 2021
2021-07-29 15:00 ET
INDYCAR Driver Conor Daly To Share His Personal Diabetes Story And Race Go-Karts With Local Youth On Wednesday, August 4th
2021-06-28 10:15 ET
Policy Change Allows Approval For Medicare Patients Living With Diabetes To Use Both Afrezza® And Continuous Glucose Monitoring Devices Beginning July 18
2021-06-25 15:35 ET
MannKind Presents Two Posters At American Diabetes Association's Virtual 81st Scientific Sessions, June 25-29
2021-06-16 14:59 ET
MannKind And United Therapeutics Achieve A Major Milestone In The Development Of Tyvaso DPI™ With New Drug Application Acceptance From The FDA
2021-06-16 10:15 ET
MannKind and United Therapeutics Achieve a Major Milestone in the Development of Tyvaso DPI™ With New Drug Application Acceptance From the FDA
2021-06-16 10:00 ET
United Therapeutics Announces FDA Acceptance of Tyvaso DPI™ New Drug Application For Priority Review
2021-06-10 10:15 ET
MannKind and Thirona Bio Join Forces to Evaluate Potential Inhaled Therapy for Fibrotic Lung Diseases
2021-06-08 21:00 ET
MannKind Corporation at the Lytham Partners Summer 2021 Investor Conference
2021-06-03 10:00 ET
MannKind Announces Data Presentation At 14th International Conference On Advanced Technologies & Treatments For Diabetes (ATTD 2021) To Be Held Virtually June 2-5
2021-05-20 13:00 ET
INDYCAR Driver Conor Daly To Share His Personal Diabetes Story And Race Go-karts With Local Youth On Tuesday, May 25th
2021-05-13 13:00 ET
MannKind Announces Partnership With Type 1 Diabetes IndyCar Driver Conor Daly
2021-05-13 13:00 ET
MannKind Announces Partnership With Type 1 Diabetes IndyCar Driver Conor Daly
2021-05-12 20:00 ET
MannKind Corporation Reports 2021 First Quarter Financial Results
2021-05-11 13:00 ET
MannKind Corporation to Participate in 2021 RBC Capital Markets Global Healthcare Conference
2021-05-05 13:00 ET
MannKind Corporation to Hold 2021 First Quarter Financial Results Conference Call on May 12, 2021
2021-04-26 13:00 ET
MannKind Reduces Legacy Debt by Approximately $49.5 Million and Restructures Remaining Obligations, including Extended Maturity, Lower Interest Rates and Increased Third Tranche
2021-04-19 10:00 ET
Mannkind and United Therapeutics Reach a Milestone in the Development of Tyvaso DPI™ With New Drug Application Submitted to the FDA
2021-04-19 10:00 ET
United Therapeutics Announces Submission of Tyvaso DPI™ New Drug Application to FDA
2021-03-16 13:00 ET
MannKind Announces Closing of Initial Purchasers’ Option to Purchase Additional Convertible Senior Notes
2021-03-15 12:00 ET
MannKind to Participate in 2022 Medicare Part D Senior Savings Model to Make Insulin More Affordable for Seniors
2021-03-10 22:00 ET
MannKind Corporation to Participate in Oppenheimer's 31st Annual Healthcare Conference
2021-03-02 22:00 ET
MannKind Corporation to Participate in H.C. Wainwright Global Life Sciences Conference
2021-03-02 11:30 ET
MannKind Corporation Prices Upsized $200.0 Million Convertible Senior Notes Offering
2021-03-01 12:00 ET
MannKind Corporation Announces Proposed Private Placement of Convertible Senior Notes
2021-02-25 13:00 ET
MannKind Corporation Reports 2020 Fourth Quarter and Full Year Financial Results
2021-02-24 13:00 ET
Vertice launches THYQUIDITY™ (levothyroxine sodium) Oral Solution
2021-02-18 22:00 ET
MannKind Corporation to Participate in 2021 SVB Leerink Global Healthcare Conference
2021-02-18 14:00 ET
MannKind Corporation to Hold 2020 Fourth Quarter and Full Year Financial Results Conference Call on February 25, 2021
2021-01-04 22:00 ET
MannKind Corporation to Participate in H.C. Wainwright Bioconnect 2021 Conference
2020-12-17 21:43 ET
MannKind and Vertice to Co-Promote Thyquidity™ (levothyroxine sodium) Oral Solution
2020-12-10 13:00 ET
James S. Shannon Transitions to Chairman of the Board of Directors for MannKind
2020-12-07 14:20 ET
MannKind Expands Its Pipeline with the Acquisition of QrumPharma, Inc.
2020-12-01 13:00 ET
MannKind and MidCap Amend Credit Facility
2020-11-30 13:00 ET
Sabrina Kay Appointed to MannKind Board of Directors
2020-11-19 22:00 ET
MannKind Receives Fourth $12.5 Million Milestone Payment from United Therapeutics
2020-11-04 21:00 ET
MannKind Corporation Reports 2020 Third Quarter Financial Results
2020-10-29 12:00 ET
MannKind Corporation to Hold 2020 Third Quarter Financial Results Conference Call on November 4, 2020
2020-09-08 12:00 ET
MannKind Corporation Participating at Upcoming Conferences
2020-08-31 13:00 ET
Kevin Kaiserman Joins MannKind as Vice President, Medical Affairs and Safety
2020-08-07 21:00 ET
MannKind Corporation to Participate in BTIG Virtual Biotechnology Conference 2020
2020-08-05 20:00 ET
MannKind Corporation Reports 2020 Second Quarter Financial Results
2020-07-29 21:00 ET
MannKind Corporation to Hold 2020 Second Quarter Financial Results Conference Call on August 5, 2020
2020-07-20 13:00 ET
Alejandro Galindo Joins MannKind as Chief Commercial Officer
2020-06-17 21:00 ET
MannKind Corporation to Present at the June 2020 Lytham Partners Virtual Investor Growth Conference
2020-06-15 13:00 ET
MannKind Presents Positive Original Analyses of Afrezza® Clinical Data at  American Diabetes Association (ADA) 80th Scientific Sessions
2020-06-13 16:00 ET
Investigator-Initiated Study Shows Switching to Afrezza® Improves Glucose Control with No Additional Hypoglycemia in T2DM
2020-05-06 20:00 ET
MannKind Corporation Reports 2020 First Quarter Financial Results
2020-04-29 21:00 ET
MannKind Corporation to Hold 2020 First Quarter Financial Results Conference Call on May 6, 2020
2020-04-15 12:00 ET
MannKind Receives Forgivable Loan under the Paycheck Protection Program
2020-03-24 13:00 ET
Jennifer Grancio Appointed to MannKind Board of Directors
2020-03-17 13:00 ET
MannKind Refocuses Pipeline Resources in Response to COVID-19 Pandemic
2020-02-25 13:00 ET
MannKind Corporation Reports 2019 Fourth Quarter and Full Year Financial Results
2020-02-24 23:25 ET
MannKind Corporation to Present at the 9th Annual SVB Leerink Global Healthcare Conference
2020-02-20 14:00 ET
MannKind Presents Novel Scientific Data at 13th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2020)
2020-02-18 14:00 ET
MannKind Corporation to Hold 2019 Fourth Quarter and Full Year Financial Results Conference Call on February 25, 2020
2020-01-06 13:00 ET
Afrezza® (insulin human) Inhalation Powder Receives Pricing Registration in Brazil Commercial activities to commence this month
2019-12-20 14:00 ET
Study 171 Shows Hypoglycemia is Reduced with Use of Afrezza® Relative to Insulin Aspart in Type 1 Diabetes
2019-11-29 14:00 ET
MannKind Corporation to Present at the Piper Jaffray 31st Annual Healthcare Conference
2019-11-21 14:00 ET
MannKind Appoints Tony Hooper to Its Board of Directors
2019-11-06 13:00 ET
MannKind Corporation Reports 2019 Third Quarter Preliminary Financial Results
2019-11-04 14:00 ET
MannKind Receives Second $12.5 Million Milestone Payment From United Therapeutics
2019-10-30 13:00 ET
MannKind Corporation to Hold 2019 Third Quarter Financial Results Conference Call on November 6, 2019
2019-09-26 13:00 ET
MannKind Corporation to Present at the 2019 Cantor Global Healthcare Conference
2019-09-19 13:00 ET
MannKind Presents Positive Afrezza® Clinical Data from Type 1 Diabetes Study at 55th Annual Meeting of the EASD
2019-03-14 13:00 ET
MannKind to Sponsor Andretti Autosport Type 1 Diabetes Driver, Conor Daly
2019-02-26 13:00 ET
MannKind Corporation Fourth Quarter and Year-End 2018 Earnings Call
2019-02-20 22:00 ET
MannKind Presents New Scientific Data at 12th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2019)

SEC forms

Show financial reports only

SEC form 10
2024-02-27 17:23 ET
MannKind Corporation published news for 2023 q4
SEC form 8
2024-02-27 16:05 ET
MannKind Corporation published news for 2023 q4
SEC form 8
2024-02-27 16:05 ET
MannKind Corporation reported for 2023 q4
SEC form 10
2024-02-27 00:00 ET
MannKind Corporation published news for 2023 q4
SEC form 10
2023-11-07 16:11 ET
MannKind Corporation reported for 2023 q3
SEC form 8
2023-11-07 16:05 ET
MannKind Corporation reported for 2023 q3
SEC form 10
2023-11-07 00:00 ET
MannKind Corporation published news for 2023 q3
SEC form 10
2023-08-07 16:12 ET
MannKind Corporation reported for 2023 q2
SEC form 6
2023-08-07 16:06 ET
MannKind Corporation published news for 2023 q2
SEC form 10
2023-08-07 00:00 ET
MannKind Corporation published news for 2023 q2
SEC form 8
2023-08-07 00:00 ET
MannKind Corporation published news for 2023 q2
SEC form 6
2023-06-30 18:00 ET
MannKind Corporation published news for 2023 q1
SEC form 8
2023-05-09 00:00 ET
MannKind Corporation published news for 2023 q1
SEC form 10
2023-05-09 00:00 ET
MannKind Corporation published news for 2023 q1
SEC form 6
2023-03-27 16:18 ET
MannKind Corporation published news for 2022 q4
SEC form 10
2023-02-23 16:11 ET
MannKind Corporation reported for 2022 q4
SEC form 6
2023-02-23 16:06 ET
MannKind Corporation published news for 2022 q4
SEC form 8
2023-02-23 00:00 ET
MannKind Corporation reported for 2022 q4
SEC form 10
2023-02-23 00:00 ET
MannKind Corporation reported for 2022 q4
SEC form 10
2022-11-08 08:08 ET
MannKind Corporation reported for 2022 q3
SEC form 6
2022-11-08 08:04 ET
MannKind Corporation published news for 2022 q3
SEC form 8
2022-11-08 00:00 ET
MannKind Corporation reported for 2022 q3
SEC form 10
2022-11-08 00:00 ET
MannKind Corporation reported for 2022 q3
SEC form 6
2022-10-31 06:02 ET
MannKind Corporation published news for 2022 q3
SEC form 6
2022-09-26 16:30 ET
MannKind Corporation published news for 2022 q2
SEC form 10
2022-08-09 16:09 ET
MannKind Corporation reported for 2022 q2
SEC form 6
2022-08-09 16:04 ET
MannKind Corporation published news for 2022 q2
SEC form 8
2022-08-09 00:00 ET
MannKind Corporation reported for 2022 q2
SEC form 10
2022-08-09 00:00 ET
MannKind Corporation reported for 2022 q2
SEC form 6
2022-05-25 16:06 ET
MannKind Corporation published news for 2022 q1
SEC form 6
2022-05-23 16:06 ET
MannKind Corporation published news for 2022 q1
SEC form 6
2022-05-12 17:12 ET
MannKind Corporation published news for 2022 q1
SEC form 6
2022-05-05 16:39 ET
MannKind Corporation published news for 2022 q1
SEC form 10
2022-05-05 16:09 ET
MannKind Corporation reported for 2022 q1
SEC form 10
2022-05-05 00:00 ET
MannKind Corporation reported for 2022 q1
SEC form 8
2022-05-05 00:00 ET
MannKind Corporation reported for 2022 q1
SEC form 6
2022-03-30 09:05 ET
MannKind Corporation published news for 2021 q4
SEC form 10
2022-02-24 16:11 ET
MannKind Corporation published news for 2021 q4
SEC form 6
2022-02-24 16:06 ET
MannKind Corporation published news for 2021 q4
SEC form 8
2022-02-24 00:00 ET
MannKind Corporation published news for 2021 q4
SEC form 10
2022-02-24 00:00 ET
MannKind Corporation published news for 2021 q4
SEC form 6
2022-01-18 07:00 ET
MannKind Corporation published news for 2021 q4
SEC form 6
2021-12-27 06:31 ET
MannKind Corporation published news for 2021 q3
SEC form 10
2021-11-09 16:12 ET
MannKind Corporation published news for 2021 q3
SEC form 6
2021-11-09 16:05 ET
MannKind Corporation published news for 2021 q3
SEC form 8
2021-11-09 00:00 ET
MannKind Corporation published news for 2021 q3
SEC form 10
2021-11-09 00:00 ET
MannKind Corporation published news for 2021 q3
SEC form 6
2021-10-18 16:02 ET
MannKind Corporation published news for 2021 q3
SEC form 6
2021-09-29 16:06 ET
MannKind Corporation published news for 2021 q2
SEC form 6
2021-08-16 16:15 ET
MannKind Corporation published news for 2021 q2
SEC form 6
2021-08-13 17:36 ET
MannKind Corporation published news for 2021 q2
SEC form 10
2021-08-11 16:11 ET
MannKind Corporation published news for 2021 q2
SEC form 6
2021-08-11 16:05 ET
MannKind Corporation published news for 2021 q2
SEC form 8
2021-08-11 00:00 ET
MannKind Corporation published news for 2021 q2
SEC form 10
2021-08-11 00:00 ET
MannKind Corporation published news for 2021 q2
SEC form 6
2021-06-16 18:16 ET
MannKind Corporation published news for 2021 q1
SEC form 6
2021-05-25 06:06 ET
MannKind Corporation published news for 2021 q1
SEC form 10
2021-05-12 16:12 ET
MannKind Corporation published news for 2021 q1
SEC form 6
2021-05-12 16:08 ET
MannKind Corporation published news for 2021 q1
SEC form 8
2021-05-12 00:00 ET
MannKind Corporation published news for 2021 q1
SEC form 10
2021-05-12 00:00 ET
MannKind Corporation published news for 2021 q1
SEC form 6
2021-04-26 06:07 ET
MannKind Corporation published news for 2021 q1
SEC form 6
2021-04-07 17:08 ET
MannKind Corporation published news for 2021 q1
SEC form 6
2021-03-05 06:06 ET
MannKind Corporation published news for 2020 q4
SEC form 10
2021-02-25 08:11 ET
MannKind Corporation published news for 2020 q4
SEC form 6
2021-02-25 08:05 ET
MannKind Corporation published news for 2020 q4
SEC form 6
2020-12-30 08:11 ET
MannKind Corporation published news for 2020 q3
SEC form 6
2020-12-10 08:13 ET
MannKind Corporation published news for 2020 q3
SEC form 6
2020-12-07 17:08 ET
MannKind Corporation published news for 2020 q3
SEC form 6
2020-12-01 08:05 ET
MannKind Corporation published news for 2020 q3
SEC form 6
2020-11-30 16:05 ET
MannKind Corporation published news for 2020 q3
SEC form 10
2020-11-04 16:11 ET
MannKind Corporation published news for 2020 q3
SEC form 6
2020-11-04 16:05 ET
MannKind Corporation published news for 2020 q3